Envoy Medical

COCH · NASDAQ

$0.6345−$0.0195 (−2.98%)TodayMarket closed ·
Prev close $0.654

About COCH

Envoy Medical, Inc. is a hearing health company, which engages in providing medical technologies across the hearing loss spectrum. The company is headquartered in White Bear Lake, Minnesota and currently employs 43 full-time employees. The company went IPO on 2021-03-02. The firm is engaged in providing medical technologies across the hearing loss spectrum, all designed to shift the paradigm within the hearing industry and bring both providers and patients the hearing devices they require. Its hearing solutions include hearing aids, middle ear implants, bone conduction devices and cochlear implants. The bone conduction hearing device has two components: an external component and a surgically implanted fixture placed in the bone behind the ear. Its bone conduction hearing device offers amplification without ear mold in the ear. Its hearing aids are devices that amplify sound for those with mild to moderate hearing loss. Its Esteem is a fully implanted active middle ear implant designed to improve the hearing of adults diagnosed with moderate to severe sensorineural hearing loss. Cochlear implants are a solution for people with moderate-to-profound sensorineural hearing loss.

Employees
43
Headquarters
White Bear Lake, Minnesota
Listed
Mar 2, 2021
Sector
Health Care
Industry
Health Care Equipment & Supplies

COCH key statistics

Market cap
49.11M
Price-earnings ratio
0.00
Dividend yield
0.00%
Average volume
66.22K
Volume
155.78K
Open price
$0.6574
High today
$0.6892
Low today
$0.6258
52 Week high
$0.9539
52 Week low
$0.3625

Envoy Medical (COCH) at a glance

Envoy Medical (COCH) last traded at $0.6345, with a market cap of 49.11M, a price-to-earnings ratio of 0.00 and a dividend yield of 0.00%.

Today the stock has traded between $0.6258 and $0.6892. The current price is 1.4% above the day's low and 7.9% below its high.

Volume so far is 155.78K shares, above the average of 66.22K shares a day.

Over the past year Envoy Medical has ranged from $0.3625 to $0.9539, and now sits 46% of the way up that range.

Envoy Medical met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.07 per share against an estimate of -$0.0816.

The average analyst price target is $2.04, 221.5% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $2.04
Low
$2.02
Now
$0.6345
High
$2.10

COCH earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 31.9% on average.

  1. Q2 FY24: reported -$0.27 per share against an estimate of -$0.2576
  2. Q3 FY24: reported -$0.37 per share against an estimate of -$0.2788
  3. Q4 FY24: reported -$0.46 per share against an estimate of -$0.3298
  4. Q1 FY25: reported -$0.29 per share against an estimate of -$0.3468
  5. Q2 FY25: reported -$0.32 per share against an estimate of -$0.3162
  6. Q3 FY25: reported -$0.34 per share against an estimate of -$0.3162
  7. Q1 FY26: reported -$0.05 per share against an estimate of -$0.1428
  8. Q2 FY26: reported -$0.07 per share against an estimate of -$0.0816

COCH news

  • Press releaseNewsfile

    Envoy Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14th-16th

  • Vandana Singh

    EXCLUSIVE: Envoy Medical Hits Key Clinical Trial Milestone for Fully Implanted Ear Implant

  • Vandana Singh

    EXCLUSIVE: Envoy Medical Builds Momentum With Improved Cochlear Implant Trial Results

  • Press releaseNewsfile

    Envoy Medical Highlights First Clinical Data Presentations from Pivotal Clinical Study of Fully Implanted Acclaim(R) Cochlear Implant

  • Press releaseNewsfile

    Envoy Medical Provides Business Update Following Transformative Financing and Positive Progress in Clinical Trial

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Press releaseNewsfile

    Envoy Medical to Host Fireside Chat with CEO Brent Lucas and the First Acclaim(R) Cochlear Implant Patient

  • Press releaseNewsfile

    Envoy Medical Achieves Six-Month Milestone with First 10 Patients in Acclaim(R) Cochlear Implant Clinical Trial

Similar companies

Companies in the same industry as Envoy Medical

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.